12,618 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Baader Bank Aktiengesellschaft

Key Points

• Baader Bank Aktiengesellschaft acquired 12,618 shares of TG Therapeutics, Inc. for approximately $492,000 in the 1st quarter, highlighting growing institutional interest in the biopharmaceutical company.
• According to analysts, TG Therapeutics has been upgraded to a "hold" rating by Goldman Sachs with a price target of $37.00, while the average target price is set at $43.80.
• TG Therapeutics reported a revenue increase of 90.4% year-over-year, with earnings missing the consensus estimate, indicating mixed financial performance amid growth opportunities.

Baader Bank Aktiengesellschaft bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,618 shares of the biopharmaceutical company's stock, valued at approximately $492,000.

Other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. raised its holdings in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 433 shares during the last quarter. Vermillion Wealth Management Inc. purchased a new position in shares of TG Therapeutics during the fourth quarter worth $30,000. USA Financial Formulas purchased a new position in shares of TG Therapeutics during the first quarter worth $57,000. Finally, Quadrant Capital Group LLC raised its holdings in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded down $0.48 on Friday, hitting $35.02. The company's stock had a trading volume of 2,316,464 shares, compared to its average volume of 1,512,933. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. TG Therapeutics, Inc. has a 1 year low of $16.65 and a 1 year high of $46.48. The firm has a fifty day moving average price of $36.83 and a 200-day moving average price of $36.01. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of 145.92 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% on a year-over-year basis. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares in the company, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $43.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.